The estimated Net Worth of Derek M Meisner is at least $751 mil dollars as of 17 August 2022. Mr Meisner owns over 8,334 units of X4 Pharmaceuticals stock worth over $100,157 and over the last 6 years he sold XFOR stock worth over $171,405. In addition, he makes $479,464 as Chief Legal Officer & Corp. Sec. at X4 Pharmaceuticals.
Mr has made over 8 trades of the X4 Pharmaceuticals stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 8,334 units of XFOR stock worth $5,750 on 17 August 2022.
The largest trade he's ever made was selling 15,909 units of X4 Pharmaceuticals stock on 11 February 2022 worth over $10,977. On average, Mr trades about 4,112 units every 51 days since 2018. As of 17 August 2022 he still owns at least 145,155 units of X4 Pharmaceuticals stock.
You can see the complete history of Mr Meisner stock trades at the bottom of the page.
Derek M. Meisner Esq., J.D. is the Chief Legal Officer & Corp. Sec. at X4 Pharmaceuticals.
As the Chief Legal Officer & Corp. Sec. of X4 Pharmaceuticals, the total compensation of Mr D at X4 Pharmaceuticals is $479,464. There are 3 executives at X4 Pharmaceuticals getting paid more, with Paula Ragan having the highest compensation of $2,497,790.
Mr D is 50, he's been the Chief Legal Officer & Corp. Sec. of X4 Pharmaceuticals since . There are 9 older and 4 younger executives at X4 Pharmaceuticals. The oldest executive at X4 Pharmaceuticals, Inc. is Dr. Robert David Arbeit, 73, who is the Sr. VP of Clinical Devel. and Translational Research.
Derek's mailing address filed with the SEC is 100 Acorn Park Dr 5th floor, Cambridge, MA 02140, USA.
Over the last 6 years, insiders at X4 Pharmaceuticals have traded over $2,179,690 worth of X4 Pharmaceuticals stock and bought 25,000 units worth $30,000 . The most active insiders traders include Paula Ragan, Adam S. Mostafa y Gary Bridger. On average, X4 Pharmaceuticals executives and independent directors trade stock every 19 days with the average trade being worth of $12,232. The most recent stock trade was executed by Mary Di Biase on 9 September 2024, trading 2,642 units of XFOR stock currently worth $1,744.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
X4 Pharmaceuticals executives and other stock owners filed with the SEC include: